Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Urologix's share price for the quarter that ended in Mar. 2015 was $0.076. Urologix's Shares Outstanding (EOP) for the quarter that ended in Mar. 2015 was 21.28 Mil. Therefore, Urologix's market cap for the quarter that ended in Mar. 2015 was $1.62 Mil.
Urologix's quarterly market cap
declined
from Sep. 2014 ($2.19 Mil) to Dec. 2014 ($1.49 Mil) but then
increased
from Dec. 2014 ($1.49 Mil) to Mar. 2015 ($1.62 Mil).
Urologix's annual market cap
declined
from Jun. 2012 ($11.33 Mil) to Jun. 2013 ($7.49 Mil) and
declined
from Jun. 2013 ($7.49 Mil) to Jun. 2014 ($3.67 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Urologix's Enterprise Value for Today is $0.00 Mil.
Urologix Market Cap Historical Data
The historical data trend for Urologix's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Urologix's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Urologix's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Market Cap distribution charts can be found below:
* The bar in red indicates where Urologix's Market Cap falls into.
Urologix Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Urologix's Market Cap for the fiscal year that ended in Jun. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Urologix (OTCPK:ULGX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Urologix Market Cap Related Terms
Thank you for viewing the detailed overview of Urologix's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ULGX has been successfully added to your 